UBS downgrades Ono Pharmaceutical stock to sell, slashes price target - Investing.com
| OPHLY Stock | USD 3.59 0.09 2.45% |
Slightly above 60% of Ono Pharmaceutical's investor base is looking to short. The analysis of overall sentiment of trading Ono Pharmaceutical Co pink sheet suggests that many investors are alarmed at this time. Ono Pharmaceutical's investing sentiment can be driven by a variety of factors including economic data, Ono Pharmaceutical's earnings reports, geopolitical events, and overall market trends.
Ono |
UBS downgrades Ono Pharmaceutical stock to sell, slashes price target Investing.com
Read at news.google.com
 |
Ono Pharmaceutical Fundamental Analysis
We analyze Ono Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ono Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ono Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Ono Pharmaceutical is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Ono Pharmaceutical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ono Pharmaceutical pink sheet to make a market-neutral strategy. Peer analysis of Ono Pharmaceutical could also be used in its relative valuation, which is a method of valuing Ono Pharmaceutical by comparing valuation metrics with similar companies.
Peers
Ono Pharmaceutical Related Equities
| PFE | Pfizer | 0.83 | ||||
| MRK | Merck | 0.74 | ||||
| GILD | Gilead Sciences | 0.27 | ||||
| JNJ | Johnson Johnson | 0.26 | ||||
| ABBV | AbbVie | 0.10 | ||||
| NVS | Novartis | 0.23 | ||||
| OGN | Organon | 0.33 | ||||
| SNY | Sanofi ADR | 0.40 | ||||
| RHHBY | Roche Holding | 0.51 | ||||
| AZN | AstraZeneca PLC | 0.54 | ||||
| GSK | GlaxoSmithKline PLC | 0.64 | ||||
| BMY | Bristol Myers | 0.89 | ||||
| GLAXF | GSK Plc | 1.23 | ||||
| AMGN | Amgen | 1.26 | ||||
| GRFS | Grifols SA | 3.55 | ||||
| SNPHF | Santen Pharmaceutical | 5.56 |
Additional Tools for Ono Pink Sheet Analysis
When running Ono Pharmaceutical's price analysis, check to measure Ono Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ono Pharmaceutical is operating at the current time. Most of Ono Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Ono Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ono Pharmaceutical's price. Additionally, you may evaluate how the addition of Ono Pharmaceutical to your portfolios can decrease your overall portfolio volatility.